For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
The advent of stem cell technologies has opened up new opportunities in drug discovery and development by providing new tools for drug screening, target identification, and toxicity testing. The discovery of reprogramming patient-derived somatic cells into induced pluripotent stem cells (iPSCs) has offered a promising alternative to generate large numbers of cells and varied tissue types.
Although iPSC-derived neurons have promising applications in drug discovery platforms, their use for high throughput screening (HTS) has been limited by the traditional differentiation methods as they are difficult to reproduce at scale.
Download the poster produced by BitBio and Charles River to find out more about how ioNEURONS/glut cells, differentiated from iPSCs, are overcoming these limitations,
See this poster presented by Charles River and BitBio at SfN for more information on how ioNEURONS/glut cells were differentiated from iPSCs and subsequently molecularly and functionally characterized.